The purpose of this study is to test the AdaptDx Pro agreement in Rod Intercept (RI) time with the AdaptDx tabletop (AdaptDx) in healthy subjects with normal vision.
Male or female between the ages of 22 and 49 (inclusive) at Visit 1
ETDRS BCVA letter score of 85 (Snellen equivalent of 20/20) or better at Visit 1
Able to communicate well with the Investigator and able to understand and comply with the requirements of the study
Informed of the nature of this study and has provided written informed consent in accordance with institutional, local and national regulatory guidelines
Unable to follow simple instructions, operate a response button or maintain attention for 20 minutes
Diagnosis or history of any ocular disease or disorder
Serious medical illness that will prevent the subject from performing study activities (including cardiac, hepatic, renal, respiratory, endocrinologic, neurologic, or hematologic disease) or, in the judgement of the Investigator, is likely to require surgical intervention or hospitalization at any point during the study
Presence of or history of malignancy within the past year of Visit 1 other than non-melanoma skin or squamous cell cancer or cervical carcinoma in-situ
Healthy adult individuals with no ocular disorder or disease.
Cohort
Prospective
AdaptDx Tabletop vs AdaptDx Pro
Diagnostic testTwo variations of AdaptDx dark adaptation devices.
Rod Intercept Time
the time in minutes it takes for the eye's rod photoreceptors to recover sensitivity after a bright flash of light
Click on the lead sponsor to view all of their trials.
